机器人辅助完全体内回肠代输尿管术治疗复杂长段输尿管狭窄缺损的临床研究:一项双向队列研究

注册号:

Registration number:

ChiCTR2600125434 

最近更新日期:

Date of Last Refreshed on:

2026-05-27 09:25:27 

注册时间:

Date of Registration:

2026-05-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

机器人辅助完全体内回肠代输尿管术治疗复杂长段输尿管狭窄缺损的临床研究:一项双向队列研究

Public title:

Totally Intracorporeal Robot-Assisted Ileal Ureter Replacement for Complex Unilateral or Bilateral Long-Segment Ureteral Strictures or Defects: An Ambispective Cohort Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

机器人辅助完全体内回肠代输尿管术治疗复杂长段输尿管狭窄缺损的临床研究:一项双向队列研究

Scientific title:

Totally Intracorporeal Robot-Assisted Ileal Ureter Replacement for Complex Unilateral or Bilateral Long-Segment Ureteral Strictures or Defects: An Ambispective Cohort Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李杰 

研究负责人:

李杰 

Applicant:

Jie Li 

Study leader:

Jie Li 

申请注册联系人电话:

Applicant telephone:

+86 578 228 5218

研究负责人电话:

Study leader's
telephone:

+86 578 228 5218

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lijie9783@126.com

研究负责人电子邮件:

Study leader's E-mail:

lijie9783@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省丽水市莲都区括苍路289号

研究负责人通讯地址:

浙江省丽水市莲都区括苍路289号

Applicant address:

No. 289 Kuocang Road, Liandu District, Lishui City, Zhejiang Province, China

Study leader's address:

No. 289 Kuocang Road, Liandu District, Lishui City, Zhejiang Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

丽水市中心医院

Applicant's institution:

Lishui Central Hospital

研究负责人所在单位:

丽水市中心医院

Affiliation of the Leader:

Lishui Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科研伦审2026(I)第163号(批)-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

丽水市中心医院科研伦理审查委员会

Name of the ethic committee:

Scientific Research Ethics Committee of Lishui Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-19 00:00:00

伦理委员会联系人:

董丹妮

Contact Name of the ethic committee:

Danni Dong

伦理委员会联系地址:

浙江省丽水市莲都区括苍路289号

Contact Address of the ethic committee:

No. 289 Kuocang Road, Liandu District, Lishui City, Zhejiang Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 578 2285719

伦理委员会联系人邮箱:

Contact email of the ethic committee:

16732020@qq.com

研究实施负责(组长)单位:

丽水市中心医院

Primary sponsor:

Lishui Central Hospital

研究实施负责(组长)单位地址:

浙江省丽水市莲都区括苍路289号

Primary sponsor's address:

No. 289 Kuocang Road, Liandu District, Lishui City, Zhejiang Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

丽水市中心医院

具体地址:

浙江省丽水市莲都区括苍路289号

Institution
hospital:

Lishui Central Hospital

Address:

No. 289 Kuocang Road, Liandu District, Lishui City, Zhejiang Province, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-selected Research Project (Self-funded)

研究疾病:

复杂单侧或双侧长段输尿管狭窄或缺损  

Target disease:

Complex Unilateral or Bilateral Long-Segment Ureteral Strictures or Defects

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

主要目的:评价完全体内机器人辅助回肠代输尿管术治疗复杂单侧或双侧长段输尿管狭窄/缺损的临床疗效。 次要目的:评估该术式的围手术期安全性及并发症发生率;评估该术式对患者术后肾功能的保护作用;评估患者在术后随访期内的主观成功率与功能性成功率。  

Objectives of Study:

Primary Objective: To evaluate the clinical efficacy of totally intracorporeal robot-assisted ileal ureter replacement for complex unilateral or bilateral long-segment ureteral strictures or defects.Secondary Objectives: To assess the perioperative safety and complication rate of this procedure; to evaluate its protective effect on postoperative renal function; and to assess the subjective and functional success rates during the follow-up period.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.未受控制的尿路感染; 活动性恶性肿瘤; 炎症性肠病; 广泛肠切除史,回肠长度不足以用于重建; 研究者认为不适合入组的其他情况。

Exclusion criteria:

1.Uncontrolled urinary tract infection;
2.Active malignancy;
3.Inflammatory bowel disease;
4.History of extensive bowel resection precluding ileal substitution;
5.Any other conditions deemed unsuitable for enrollment by the investigator.

研究实施时间:

Study execute time:

From 2026-05-19 00:00:00 To 2029-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-31 00:00:00 To 2028-05-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

37

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

丽水市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Lishui Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

功能性成功率

指标类型:

主要指标

Outcome:

Functional Success Rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主观成功率

指标类型:

次要指标

Outcome:

Subjective success rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能(肾小球滤过率)

指标类型:

次要指标

Outcome:

Kidney function (glomerular filtration rate)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恢复(术后首次进食时间、引流管拔除时间、术后住院天数)

指标类型:

次要指标

Outcome:

Postoperative recovery (time of first postoperative meal, time of drainage tube removal, length of postoperative hospital stay)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据去标识化处理,以唯一受试者编号代替可识别身份信息。数据存储于加密的院内系统中,访问权限严格受控。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data will be de-identified, and identifiable information will be replaced by a unique subject code. Data will be stored in an encrypted hospital system with strictly controlled access.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-05-27 09:25:12